Publications by authors named "K Appenteng"

Claim this Profile
L
Lessons learned from a multi-data source research collaboration: The mirabegron post-authorization safety study program.
Stefan de Vogel, John D Seeger, Alejandro Arana, Andrea V Margulis, Lisa J McQuay, Kwame Appenteng

Pharmacoepidemiol Drug Saf· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study.
Veena Hoffman, Jesper Hallas, Marie Linder, Andrea V Margulis, Brandon T Suehs, Kwame Appenteng

Drug Saf· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder.
Kelesitse Phiri, Jesper Hallas, Marie Linder, Andrea Margulis, Brandon Suehs, Kwame Appenteng

Curr Med Res Opin· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of cardiovascular outcomes and risk factors in the Clinical Practice Research Datalink in the United Kingdom.
Alejandro Arana, Andrea V Margulis, Cristina Varas-Lorenzo, Christine L Bui, Alicia Gilsenan, Kwame Appenteng

Pharmacoepidemiol Drug Saf· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries.
Edith M Heintjes, Irene D Bezemer, Daniel Prieto-Alhambra, Elisabeth Smits, Helen P Booth, Kwame Appenteng

Clin Epidemiol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis